Hepatoma cell apoptosis

Hepatoma cell apoptosis refers to the programmed cell death process occurring within hepatocellular carcinoma (HCC) cells. It is not a specific protein or receptor target, but rather a complex biological outcome and a major focus of oncology research aimed at eliminating malignant liver cells (Wang & Lin, 2013, Int J Cell Biol). In a healthy state, apoptosis maintains tissue homeostasis, but in hepatoma cells, this process is frequently suppressed through the mutation of tumor suppressors like p53 or the upregulation of anti-apoptotic proteins such as BCL-2 and MCL-1 (NIH, 2023, PubMed). \n\nInducing hepatoma cell apoptosis is the primary therapeutic mechanism for several systemic treatments, including multi-kinase inhibitors like Sorafenib and Lenvatinib. These drugs promote apoptosis by blocking vascular endothelial growth factor receptors (VEGFR) and platelet-derived growth factor receptors (PDGFR), thereby cutting off survival signals and inducing cellular stress (Wilhelm et al., 2004, Nature Reviews Drug Discovery). Because hepatoma cell apoptosis is a process rather than a single molecule, it is considered a phenotypic endpoint used to measure the efficacy of diverse drug classes in liver cancer management (Galle et al., 2019, Journal of Hepatology).

Other names

Programmed cell death in liver cancer cellsHCC apoptosisInduction of hepatoma cell death

Not applicable as a single molecular target; however, therapeutic agents induce this process by inhibiting pro-survival signaling pathways like MAPK/ERK and PI3K/Akt, or by activating pro-apoptotic cascades involving Caspases (NIH, 2023; Wang & Lin, 2013).